
1. Technology overview
iCUREX Inc. is a medical materials company located in Kagoshima, Japan. It develops wound care products based on chitosan hydrogel technology, supported by patents and an exclusive license over core patents registered in September 2026.
Kitosura CX is a Class III advanced controlled medical device classified as a secondary-healing hydrophilic gelling wound dressing and protective material. Pre-gelled chitosan hydrogel microparticles are injected into the wound to maintain a moist healing environment. The gel does not stick to the wound, so removal is less likely to damage new tissue, and gauze or film dressings can be layered on top as needed.
2. Highlighted features & specifications
- Class III device: Classified as an advanced controlled medical device for secondary-healing wounds.
- Chitosan hydrogel: Pre-gelled chitosan hydrogel microparticles injected into the wound.
- Moist healing: Creates a suitably moist environment to promote healing.
- Non-adherent gel: Does not fix to the wound bed, so removal is gentle on new tissue.
- Layered use: Gauze or film dressings can be placed over the gel.
3. Potential application
Wound care and plastic surgery departments could use the injectable gel on deep or irregular wounds. Home nursing and long-term care facilities could use it on pressure injuries. Distributors of medical dressings could add it to wound care ranges.
4. Benefits
Maintains a moist environment that promotes wound healing. Gel form does not adhere to the wound, so removal is less likely to damage new tissue. Can be applied into narrow or complex wound shapes. Can be combined with gauze or film dressings.
5. Market trends & opportunities
Ageing populations and diabetes increase chronic wounds and pressure injuries, driving demand for advanced moist wound care materials. Vietnamese hospitals and home-care providers treating burns, diabetic ulcers and pressure sores may look for dressings that suit deep or irregular wounds.
6. Other information
Headquartered in Kagoshima, Japan. Completed a Series A first close totaling 140 million yen in October 2026; registered a European patent on medical hydrogel in September 2026; selected for a Kagoshima prefecture growth subsidy in 2026.
One platform connecting startups, corporations, research institutions, regions and investors











Playbook & Handbook · February 6, 2026
Winning Accelerator Playbook 2026 by BambuUP
RETAIL E-COMMERCE: AI AND REAL-TIME DATA ARE TRANSFORMING HOW RETAIL BUSINESSES OPERATE








































